Last reviewed · How we verify
Pfizer Depo-medrol
Pfizer Depo-medrol is a Corticosteroid (glucocorticoid) Small molecule drug developed by Obafemi Awolowo University Teaching Hospital. It is currently in Phase 3 development for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Cerebral edema and spinal cord injury.
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation.
Methylprednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Cerebral edema and spinal cord injury.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pfizer Depo-medrol |
|---|---|
| Sponsor | Obafemi Awolowo University Teaching Hospital |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Oncology (adjunctive) |
| Phase | Phase 3 |
Mechanism of action
Methylprednisolone binds to glucocorticoid receptors in the cytoplasm, translocates to the nucleus, and modulates gene transcription to decrease production of inflammatory mediators (IL-1, IL-6, TNF-α) and reduce immune cell proliferation and migration. This broad anti-inflammatory and immunosuppressive action makes it effective across multiple inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Allergic reactions and asthma exacerbations
- Cerebral edema and spinal cord injury
- Hematologic malignancies (adjunctive therapy)
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia and mood changes
- Immunosuppression and increased infection risk
- Osteoporosis with long-term use
- Gastrointestinal upset
Key clinical trials
- Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus (EARLY_PHASE1)
- Comparative Study Between Platelet Rich Plasma and Steroid Injection in Trigger Finger Treatment (PHASE3)
- 3D Evaluation of Postoperative Edema After Third Molar Surgery (PHASE4)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (PHASE2, PHASE3)
- Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis (PHASE3)
- Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II (PHASE4)
- OCT Guided Punctal Stenosis Management (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pfizer Depo-medrol CI brief — competitive landscape report
- Pfizer Depo-medrol updates RSS · CI watch RSS
- Obafemi Awolowo University Teaching Hospital portfolio CI
Frequently asked questions about Pfizer Depo-medrol
What is Pfizer Depo-medrol?
How does Pfizer Depo-medrol work?
What is Pfizer Depo-medrol used for?
Who makes Pfizer Depo-medrol?
What drug class is Pfizer Depo-medrol in?
What development phase is Pfizer Depo-medrol in?
What are the side effects of Pfizer Depo-medrol?
What does Pfizer Depo-medrol target?
Related
- Drug class: All Corticosteroid (glucocorticoid) drugs
- Target: All drugs targeting Glucocorticoid receptor (GR)
- Manufacturer: Obafemi Awolowo University Teaching Hospital — full pipeline
- Therapeutic area: All drugs in Immunology, Rheumatology, Oncology (adjunctive)
- Indication: Drugs for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Indication: Drugs for Allergic reactions and asthma exacerbations
- Indication: Drugs for Cerebral edema and spinal cord injury
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing